Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Janux Therapeutics, Inc. has received a consensus recommendation of “Moderate Buy” from 16 research firms, with an average price target of $79.08 over the next year.
• After missing earnings estimates with an EPS of ($0.55), analysts predict a -1.38 EPS for the current fiscal year.
• Institutional investors own 75.39% of Janux Therapeutics' stock, with significant increases in holdings from various hedge funds during the first quarter.

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the sixteen research firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $79.0833.

A number of equities research analysts have commented on the company. Piper Sandler assumed coverage on Janux Therapeutics in a research note on Monday, August 18th. They issued an "overweight" rating and a $42.00 price target for the company. Truist Financial started coverage on Janux Therapeutics in a research note on Wednesday, September 10th. They issued a "buy" rating and a $100.00 price objective for the company. Barclays started coverage on Janux Therapeutics in a research note on Wednesday, September 17th. They issued an "overweight" rating and a $47.00 price objective for the company. Stifel Nicolaus restated a "buy" rating and issued a $45.00 price objective on shares of Janux Therapeutics in a research note on Wednesday, September 10th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Janux Therapeutics in a research note on Wednesday, October 8th.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $24.46 on Friday. The stock has a 50-day moving average of $24.31 and a two-hundred day moving average of $25.29. Janux Therapeutics has a one year low of $21.73 and a one year high of $71.71. The stock has a market cap of $1.47 billion, a PE ratio of -13.59 and a beta of 2.82.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.07). As a group, sell-side analysts predict that Janux Therapeutics will post -1.38 EPS for the current fiscal year.

Institutional Trading of Janux Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of JANX. GAMMA Investing LLC grew its holdings in Janux Therapeutics by 1,574.0% during the first quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock worth $45,000 after acquiring an additional 1,574 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in Janux Therapeutics by 54.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 9,033 shares of the company's stock worth $244,000 after acquiring an additional 3,168 shares during the period. KBC Group NV acquired a new stake in Janux Therapeutics during the first quarter worth about $66,000. Bank of New York Mellon Corp grew its holdings in Janux Therapeutics by 13.3% during the first quarter. Bank of New York Mellon Corp now owns 89,370 shares of the company's stock worth $2,413,000 after acquiring an additional 10,511 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Janux Therapeutics by 6.5% during the first quarter. China Universal Asset Management Co. Ltd. now owns 11,855 shares of the company's stock worth $320,000 after acquiring an additional 727 shares during the period. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.